Overcoming the challenges of scaling endothelial cells.
Manufacturing endothelial cells is notoriously hard to scale, with many research-grade protocols delivering low-to-moderate purity and requiring enrichment steps that don’t translate into GMP production. Echo™-Endothelial, available only from Cellistic, solves this by delivering >90% lineage specificity through a fully GMP-ready manufacturing platform, unlocking the therapeutic potential of endothelial cells across vascularization-driven applications. By integrating a pre-established iPSC-to-endothelial differentiation process with scalable GMP manufacturing and a complete CMC framework, Echo™-Endothelial provides developers with predictable performance, consistent endothelial function, and regulatory alignment—reducing development risk and enabling a confident path toward IND/IMPD submission.
Accelerate speed to clinic through a pre-established, iPSC-based GMP manufacturing platform
Reduce process and analytical development challenges with pre-built platform and pre-established starting materials
Boost scalability using stirred-tank bioreactors
Secure clear IP positioning and licensing framework
Ensure regulatory readiness and GMP compliance at our EMA-certified, and FDA and PMDA-compliant manufacturing facility
Work with a proven endothelial manufacturing partner delivering consistent >90% purity across batches — without purification steps
How to succeed in endothelial cell manufacturing.
Endothelial cells can show a clear stubborn streak when pushed to scale. That’s where our Echo™-Endothelial platform – and our expertise in how endothelial cells function – come in. Echo™-Endothelial integrates iPSC manufacturing expertise with standardized GMP workflows to ensure scalability, reproducibility, and regulatory alignment for your endothelial program.
Qualified iPSC starting materials
Manufacturing starts from pre-established GMP iPSC master cell banks (MCBs).
Genomic stability, low-passage lines, and full traceability
Long-term supply security
Optional integration of client-specific edits via Pulse™ and STAR-CRISPR™
Scalable 3D bioreactor expansion
Controlled, reproducible expansion in automated stirred-tank bioreactors
Clinical-scale output exceeding 20B cells per batch
Consistent viability, purity, and phenotype maintained across scale
Pre-established batch records and qualified GMP raw materials
Give your endothelial program the start, middle and finish it deserves.
The Echo™-Endothelial platform might be exactly the manufacturing ally to advance your endothelial program on the best possible trajectory – and at the fastest speed – from beginning to end. So why wait to put it to work?
Everything you need to advance efficiently and effectively.
Echo™-Endothelial produces a full suite of GMP-grade endothelial cell materials and documentation packages ready for translational and clinical advancement.
GMP-manufactured endothelial cells
Delivered at scales suitable for Phase 1 clinical studies
Comprehensive documentation package
Certificates of Analysis
Full traceability logs
Batch records
QC release panel
Regulatory-ready CMC documentation
IP under one roof
Direct access to STAR-CRISPR™, Allo Chassis™, and Echo™ manufacturing with no third-party entanglements
Consistent, reproducible output
Functionally relevant and physiologically reflective of in vivo endothelial biology
Reproducible with tight biological variability control
Fully cGMP compliant, suitable for in vitro modeling, screening, and clinical-scale manufacturing
The platform that delivers momentum from the word “Go!”
When you trust Cellistic and the Echo™-Endothelial platform to push your endothelial manufacturing program forward, you unleash a system purpose-built to advance iPSC-based cell therapy and regenerative medicine programs. Let’s see if Echo™-Endothelial is a good match for you.
News
